



## OpGen to Provide Business Update and Financial Results for the First Quarter 2022 on May 12th at 4:30 p.m. Eastern Time

April 28, 2022

ROCKVILLE, Md., April 28, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its first quarter 2022 financial results after the close of the U.S. financial markets on Thursday, May 12<sup>th</sup>, 2022. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities.

### Conference Call Details

|                               |   |
|-------------------------------|---|
| U.S. Dial-in Number:          | 1-877-704-4453  |
| International Dial-in Number: | 1-201-389-0920  |
| Webcast:                      | <a href="https://services.choruscall.com/mediaframe/webcast.html?webcastid=n37Dadqy">https://services.choruscall.com/mediaframe/webcast.html?webcastid=n37Dadqy</a> |
| Conference ID:                | 13729189  |

### Replay Details

|                               |                |
|-------------------------------|----------------|
| U.S. Dial-in Number:          | 1-844-512-2921 |
| International Dial-in Number: | 1-412-317-6671 |
| Replay PIN:                   | 13729189       |

Following the conclusion of the conference call, a replay will be available through May 26<sup>th</sup>, 2022. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company's website at [www.opgen.com](http://www.opgen.com). A replay of the webcast will be available following the conclusion of the call and will be archived on the Company's website under *Financials & Filings*.

### About OpGen, Inc.

OpGen, Inc. (Rockville, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen's product portfolio includes Unyvero<sup>®</sup>, Acuitas<sup>®</sup> AMR Gene Panel and the ARES Technology Platform including ARESdb<sup>®</sup>, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

For more information, please visit [www.opgen.com](http://www.opgen.com).

### OpGen:

Oliver Schacht  
President and CEO  
[InvestorRelations@opgen.com](mailto:InvestorRelations@opgen.com)

### OpGen Press Contact:

Matthew Bretzius  
FischTank Marketing and PR  
[matt@fishtankpr.com](mailto:matt@fishtankpr.com)

### OpGen Investor Contact:

Alyssa Factor  
Edison Group  
[afactor@edisongroup.com](mailto:afactor@edisongroup.com)



Source: OpGen, Inc.